ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Ying Yuan
Matched on ORCID iD 0000-0003-3163-480X; OpenAlex author ID A5019360674; NIH RePORTER profile ID 8687320. Sources: ClinicalTrials.gov.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 2 (principal investigator on 2)
- Grants
- 2
- Labs led
- 1
- Collaborators
- 51
2017: 1 trial · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 1 paper, 1 trial · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 grants
Papers 7
- Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarci… Co-author DOI 10.1136/jitc-2023-006822↗
- Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
- Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. Last author DOI 10.1200/po.21.00212↗
- Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of a multicenter randomized controlled tri… Co-author DOI 10.1016/j.cct.2019.105898↗
- Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
- Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
- INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study o… Co-author DOI 10.1097/mpa.0000000000001172↗
Trials 2
- Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study Principal investigator NCT06651580↗
- Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Principal investigator NCT03058926↗
Grants 2
Closest collaborators
The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Liang Li · 2 shared grants, 2026 · strength 2.04
- Suyu Liu · 1 shared grant, 2026 · strength 0.77
- Anirban Maitra · 1 shared grant, 2026 · strength 0.77
- Ziding Feng · 1 shared grant, 2026 · strength 0.77
- Rebecca S. Slack Tidwell · 3 shared papers, 2020–2023 · strength 0.43
- Paper Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. DOI 10.1200/po.21.00212↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Shubham Pant · 3 shared papers, 2020–2024 · strength 0.37
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Ching-Wei David Tzeng · 3 shared papers, 2020–2024 · strength 0.37
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Robert A. Wolff · 2 shared papers, 2023–2024 · strength 0.28
- Paper Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal … DOI 10.1136/jitc-2023-006822↗
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Brian G. Czito · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Lauren Elizabeth Colbert · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Jessica M. Frakes · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Todd Anthony Aguilera · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Manisha Palta · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Joseph M. Herman · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Shalini Moningi · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Sarah E. Hoffe · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Cullen M. Taniguchi · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Manoop S. Bhutani · 2 shared papers, 2020–2023 · strength 0.21
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in… DOI 10.1016/j.ijrobp.2020.09.022↗
- Melena D. Bellin · 3 shared papers, 2018–2020 · strength 0.19
- Paper Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of… DOI 10.1016/j.cct.2019.105898↗
- Paper Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic C… DOI 10.1097/mpa.0000000000001168↗
- Paper INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPI… DOI 10.1097/mpa.0000000000001172↗
- José Serrano · 3 shared papers, 2018–2020 · strength 0.19
- Paper Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of… DOI 10.1016/j.cct.2019.105898↗
- Paper Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic C… DOI 10.1097/mpa.0000000000001168↗
- Paper INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPI… DOI 10.1097/mpa.0000000000001172↗
- Michael James Overman · 1 shared paper, 2024 · strength 0.16
- Milind M. Javle · 1 shared paper, 2024 · strength 0.16
- Chantale Bernatchez · 1 shared paper, 2024 · strength 0.16
- Donastas Sakellariou-Thompson · 1 shared paper, 2024 · strength 0.16
- Rodabe Navroze Amaria · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.